Q1 Earnings Forecast for GANX Issued By Roth Capital

Gain Therapeutics, Inc. (NASDAQ:GANX) – Equities researchers at Roth Capital issued their Q1 2026 earnings estimates for Gain Therapeutics in a research report issued to clients and investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan forecasts that the company will post earnings of ($0.27) per share for the quarter. Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2026 earnings at ($0.29) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.30) EPS.

Gain Therapeutics (NASDAQ:GANX) last posted its earnings results on Thursday, March 27th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07.

GANX has been the topic of several other reports. Roth Mkm restated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Monday, March 17th. Scotiabank started coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a report on Friday, March 28th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Performance

Shares of GANX opened at $1.81 on Tuesday. The firm has a market capitalization of $48.01 million, a P/E ratio of -1.65 and a beta of 0.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a one year low of $0.89 and a one year high of $4.04. The business has a fifty day moving average of $2.20 and a 200 day moving average of $2.07.

Hedge Funds Weigh In On Gain Therapeutics

A number of large investors have recently made changes to their positions in the company. Sprott Inc. bought a new stake in shares of Gain Therapeutics during the fourth quarter worth $30,000. Benedict Financial Advisors Inc. purchased a new position in Gain Therapeutics in the fourth quarter worth $35,000. Bridgeway Capital Management LLC purchased a new stake in Gain Therapeutics in the fourth quarter valued at about $65,000. Northern Trust Corp boosted its stake in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its stake in shares of Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after buying an additional 44,750 shares during the period. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.